BRIEF-Scynexis And GSK Resolve Their Disagreement Related To The Restart Of The Phase 3 MARIO Study

Reuters10-15

Oct 15 (Reuters) - GSK plc GSK.L:

SCYNEXIS AND GSK RESOLVE THEIR DISAGREEMENT RELATED TO THE RESTART OF THE PHASE 3 MARIO STUDY
SCYNEXIS INC - TO RECEIVE $22 MILLION PAYMENT RELATED TO PHASE 3 MARIO STUDY
SCYNEXIS INC - TO TERMINATE PHASE 3 MARIO STUDY
SCYNEXIS INC - GSK PAYMENT EXTENDS SCYNEXIS CASH RUNWAY TO OVER TWO YEARS
SCYNEXIS INC - TO RECEIVE ADDITIONAL $2.3 MILLION FOR WIND-DOWN ACTIVITIES

Source text: ID:nGNX9LzfT5

Further company coverage: GSK.L

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2575781773?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-15 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575781773","market":"us","top_or_hot":-1,"title":"BRIEF-Scynexis And GSK Resolve Their Disagreement Related To The Restart Of The Phase 3 MARIO Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Scynexis And GSK Resolve Their Disagreement Related To The Restart Of The Phase 3 MARIO Study</title></head><body><p><span>Oct 15 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/GLAXD\">GSK plc</a> <span>GSK.L</span>:</p><ul><li><p>SCYNEXIS AND GSK RESOLVE THEIR DISAGREEMENT RELATED TO THE RESTART OF THE PHASE 3 MARIO STUDY</p></li><li><p>SCYNEXIS INC - TO RECEIVE $22 MILLION PAYMENT RELATED TO PHASE 3 MARIO STUDY</p></li><li><p>SCYNEXIS INC - TO TERMINATE PHASE 3 MARIO STUDY</p></li><li><p>SCYNEXIS INC - GSK PAYMENT EXTENDS SCYNEXIS CASH RUNWAY TO OVER TWO YEARS</p></li><li><p>SCYNEXIS INC - TO RECEIVE ADDITIONAL $2.3 MILLION FOR WIND-DOWN ACTIVITIES</p></li></ul><p>Source text: <span>ID:nGNX9LzfT5</span></p><p>Further company coverage: <span>GSK.L</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Scynexis And GSK Resolve Their Disagreement Related To The Restart Of The Phase 3 MARIO Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Scynexis And GSK Resolve Their Disagreement Related To The Restart Of The Phase 3 MARIO Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-15 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Scynexis And GSK Resolve Their Disagreement Related To The Restart Of The Phase 3 MARIO Study</title></head><body><p><span>Oct 15 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/GLAXD\">GSK plc</a> <span>GSK.L</span>:</p><ul><li><p>SCYNEXIS AND GSK RESOLVE THEIR DISAGREEMENT RELATED TO THE RESTART OF THE PHASE 3 MARIO STUDY</p></li><li><p>SCYNEXIS INC - TO RECEIVE $22 MILLION PAYMENT RELATED TO PHASE 3 MARIO STUDY</p></li><li><p>SCYNEXIS INC - TO TERMINATE PHASE 3 MARIO STUDY</p></li><li><p>SCYNEXIS INC - GSK PAYMENT EXTENDS SCYNEXIS CASH RUNWAY TO OVER TWO YEARS</p></li><li><p>SCYNEXIS INC - TO RECEIVE ADDITIONAL $2.3 MILLION FOR WIND-DOWN ACTIVITIES</p></li></ul><p>Source text: <span>ID:nGNX9LzfT5</span></p><p>Further company coverage: <span>GSK.L</span></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0225771236.USD","symbol_name":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nFWN3VW2ET:1","article_id":"2575781773","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575781773","pubTimestamp":1760529747,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Scynexis And GSK Resolve Their Disagreement Related To The Restart Of The Phase 3 MARIO StudyOct 15 (Reuters) - GSK plc GSK.L:SCYNEXIS AND GSK RESOLVE THEIR DISAGREEMENT RELATED TO THE RESTART O","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU0971552673.USD":"Allianz European Equity Dividend Cl AM DIS H2-USD","LU1035777561.USD":"AB SICAV I - EUROPEAN EQUITY PORTFOLIO \"A\" (USDHDG) ACC","LU1400636491.USD":"Allianz Europe Income and Growth Cl AMg DIS H2-USD","SCYX":"SCYNEXIS Inc","LU1400636657.SGD":"Allianz Europe Income and Growth Cl AMg DIS H2-SGD","LU1481600234.SGD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"ASC\" (SGDHDG) INC","LU1098665638.USD":"FRANKLIN MUTUAL EUROPEAN \"A\" (USDHDG) H1 ACC","IE00BQJZX424.USD":"FRANKLIN MV EUROPEAN EQUITY GROWTH AND INCOME \"A\" (USDHDG) INC","LU1228905037.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) ACC","IE00BWDBJ516.SGD":"Legg Mason QS - MV European Equity Growth and Income A Mdis SGD-H Plus","LU1046248800.SGD":"Allianz European Equity Dividend Cl AM DIS H2-SGD","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0161305163.EUR":"SCHRODER ISF EUROPEAN VALUE \"A\" (EUR) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0575583348.USD":"SCHRODER ISF UK EQUITY \"A\" (USD) INC AV","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK5011":"制药","LU1228905540.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) INC 2","LU1202635105.USD":"ALLIANZ EUROPE INCOME AND GROWTH \"AM\" (USDHDG) INC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","GSK.UK":"葛兰素史克","LU1064927863.SGD":"JPMorgan Funds - Europe Dynamic A (acc) SGD-H","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1487256676.USD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"ZUH\" (USDHDG) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0058720904.USD":"联博国际健康护理基金A","LU1670756490.USD":"ALLIANZ EUROPE INCOME AND GROWTH \"AT\" (USDHDG) ACC","LU0109981661.USD":"FRANKLIN MUTUAL EUROPEAN \"A\" (USD) ACC","LU1302929846.USD":"ALLIANZ EUROPEAN EQUITY DIVIDEND \"AMG\" (USDHDG) INC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1400636574.HKD":"ALLIANZ EUROPE INCOME AND GROWTH \"AMG\" (HKDHDG) INC","LU1309081286.SGD":"SCHRODER ISF EUROPEAN VALUE \"A\" (SGDHDG) ACC","IE0034235071.USD":"PINEBRIDGE EUROPE RESEARCH ENHANCED EQUITY \"A\" (USD) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","BK4007":"制药","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU0971552830.HKD":"ALLIANZ EUROPEAN EQUITY DIVIDEND \"AM\" (HKDHDG) INC","LU0545562505.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) INC","LU1481599808.USD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"AUC\" (USDHDG) INC","LU1015430645.USD":"SCHRODER ISF UK EQUITY \"A\" (USDHDG) ACC","LU1645745479.HKD":"ALLIANZ EUROPE INCOME AND GROWTH \"AM\" (HKDHDG) INC"},"translate_title":"简介-Scynexis和GSK解决了与重启3期MARIO研究相关的分歧","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SCYX":0.9,"GSK.UK":0.9},"content_text":"BRIEF-Scynexis And GSK Resolve Their Disagreement Related To The Restart Of The Phase 3 MARIO StudyOct 15 (Reuters) - GSK plc GSK.L:SCYNEXIS AND GSK RESOLVE THEIR DISAGREEMENT RELATED TO THE RESTART OF THE PHASE 3 MARIO STUDYSCYNEXIS INC - TO RECEIVE $22 MILLION PAYMENT RELATED TO PHASE 3 MARIO STUDYSCYNEXIS INC - TO TERMINATE PHASE 3 MARIO STUDYSCYNEXIS INC - GSK PAYMENT EXTENDS SCYNEXIS CASH RUNWAY TO OVER TWO YEARSSCYNEXIS INC - TO RECEIVE ADDITIONAL $2.3 MILLION FOR WIND-DOWN ACTIVITIESSource text: ID:nGNX9LzfT5Further company coverage: GSK.L","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2575781773","isCrawlerRequest":true}